journal article·2025-04

Designed microchannel-based lipid nanoparticles encapsulated siRNA targeting gasdermin D for sepsis management via pulmonary delivery

Jie Liu, Ranran Li, Qinghui Fu, Yani Yang, Xiaoling Liu, Fan Xu, Hongping Qu, Jianxin Wang, Weigen Lu, Jun He

Nano Today· Volume 61
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Inflammasome and immune disorders · Erythrocyte Function and Pathophysiology · Curcumin's Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (60)

Show source-provided references
1. The third international consensus definitions for sepsis and septic shock (Sepsis-3)10.1001/jama.2016.0287 ↗
2. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation10.1038/s41590-020-0669-6 ↗
3. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis - a randomized controlled trial10.1001/jama.283.13.1723 ↗
4. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis10.1097/CCM.0b013e3181e7c5c9 ↗
5. Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis10.1097/CCM.0b013e3181b07b78 ↗
6. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock10.1016/S0140-6736(05)60602-2 ↗
7. Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis10.1097/CCM.0b013e3182982add ↗
8. A recombinant human receptor antagonist to interleukin-1 improves survival after lethal endotoxemia in mice10.1084/jem.173.4.1029 ↗
9. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome-A randomized, open-label, placebo-controlled multicenter trial10.1097/00003246-199401000-00008 ↗
10. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial10.1097/00003246-199707000-00010 ↗
11. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis10.1097/00003246-200003000-00006 ↗
12. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: phase IIb, multicenter, randomized, placebo-controlled, clinical trial10.1097/01.CCM.0000063267.79824.DB ↗
13. S. Con Mort Tri Plate-Act Fac Ace, Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial10.1097/01.CCM.0000108867.87890.6D ↗
14. Drotrecogin alfa (activated) in adults with septic shock10.1056/NEJMoa1202290 ↗
15. Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A Bayesian analysis10.1371/journal.pone.0002291 ↗
16. Structural mechanism for GSDMD targeting by autoprocessed caspases in pyroptosis10.1016/j.cell.2020.02.002 ↗
17. The role of gasdermin-D-mediated pryoptosis in organ injury and its therapeutic implications10.1080/15476278.2023.2177484 ↗
18. Active release of eCIRP via gasdermin D channels to induce inflammation in sepsis10.4049/jimmunol.2101004 ↗
19. GSDMD-mediated pyroptosis promotes cardiac remodeling in pressure overload10.1080/10641963.2023.2189138 ↗
20. Mechanism and regulation of gasdermin-mediated cell death10.1101/cshperspect.a036400 ↗
21. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death10.1038/nature15514 ↗
22. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling10.1038/nature15541 ↗
23. Downregulating gasdermin D reduces severe acute pancreatitis associated with pyroptosis
24. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores10.1038/nature18629 ↗
25. Gasdermin D is an executor of pyroptosis and required for interleukin-1 beta secretion10.1038/cr.2015.139 ↗
26. The role and mechanism of pyroptosis and potential therapeutic targets in sepsis: a review10.3389/fimmu.2021.711939 ↗
27. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases10.1111/imr.12534 ↗
28. Inflammasome activation at the crux of severe
29. D. Gilad, G. Nicole L K, G. Xin, Y. Zhiyuan, M. Kathryn M, Z. Orlando, H. Peter W, H. Hiroyu, S. Stefanie, M.-A. Isa, G.J.N. Warner C, Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection, 505 (2013).
30. M. Brienne A, D. Vishva M, P.J.T.N. Christopher, Fiery Cell Death: Pyroptosis in the Central Nervous System, 43 (2019).10.1016/j.tins.2019.11.005 ↗
31. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice10.1016/j.jhep.2017.11.040 ↗
32. Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS/NF-κB/NLRP3/GSDMD signal axis in non-small cell
33. G. Jianwei, Q. Xiangyu, X. Guangmin, L. Hongbing, Z. Fang, L. Tangfeng, S.J.O.R. Yong, Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non‑small cell lung cancer, 40 (2018).
34. K. Apurva, M.R. K. Subbarao, S. Pedro H V, V.W. Lieselotte, V.G. Hanne, K. Hiroto, T. Heather, V. Peter, L. Hongbo R, X. Ramnik J, C. Hongbo, L.J.J.E.M. Mohamed, GSDMD is critical for autoinflammatory pathology in a mouse model of Familial Mediterranean Fever, 215 (2018).10.1084/jem.20172060 ↗
35. X. Jianqiu, W. Chun, Y. Juo-Chin, A. Yael, X. Canxin, K. Dustin, C. Roberto, A.-A. Yousef, K. Thirumala-Devi, L. Daniel C, M.J.P.B. Gabriel, Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice, 16 (2018).10.1371/journal.pbio.3000047 ↗
36. Targeting the gasdermin D as a strategy for ischemic stroke therapy10.1016/j.bcp.2021.114585 ↗
37. L. Sheng, W. Yuqing, Y. Dongxue, W. Chunyan, M. Chunmei, L. Xue, M. Paul N, W. Bingwei, H. Gang, Y.J.J.E.M. Shuo, Gasdermin D in peripheral myeloid cells drives neuroinflammation in experimental autoimmune encephalomyelitis, 216 (2019).
38. Pyroptosis executive protein GSDMD as a biomarker for diagnosis and identification of Alzheimer
39. R. Wenjuan, L. Sheng, X. Hong, X. Ming, S.J.I.J.N. Jingping, Baicalein Attenuates Neuroinflammation by Inhibiting NLRP3/caspase-1/GSDMD Pathway in MPTP Induced Mice Model of Parkinson's Disease, 23 (2020).10.1093/ijnp/pyaa060 ↗
40. Gasdermin D-mediated pyroptosis: mechanisms, diseases
41. RNAi-based therapeutics and novel RNA bioengineering technologies10.1124/jpet.122.001234 ↗
42. Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis10.1016/j.jconrel.2022.01.038 ↗
43. The growth of siRNA-based therapeutics: updated clinical studies10.1016/j.bcp.2021.114432 ↗
44. Silencing of gasdermin D by siRNA-loaded PEI-chol lipopolymers potently relieves acute gouty arthritis through inhibiting pyroptosis10.1021/acs.molpharmaceut.0c00229 ↗
45. Microfluidics for development of lipid nanoparticles: paving the way for nucleic acids to the clinic
46. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery10.1016/j.jconrel.2022.02.017 ↗
47. Research strategies for precise manipulation of micro/nanoparticle drug delivery systems using microfluidic technology: a review10.1055/s-0044-1786180 ↗
48. Manufacturing considerations for the development of lipid nanoparticles using microfluidics10.3390/pharmaceutics12111095 ↗
49. Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids*10.1016/j.addr.2022.114197 ↗
50. Optimal self-assembly of lipid nanoparticles (LNP) in a ring micromixer10.1038/s41598-022-13112-5 ↗
51. Evaluation of the quality, safety and efficacy of messenger RNA vaccines for the prevention of infectious diseases
52. E.O.C. Authority, EU Official Control Authority. Official Control Authority Batch Release Of Pandemic COVID-19 Vaccine (MRNA), 2021.
53. U.S. FDA, Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation, 2018.
54. Ian MaLachlan · 2006
55. G. Cong, Z. Kefan, Y. Ying, L. Chan, N. Beibei, L. Jiangman, W. Yeming, Z. Xiaoyan, W. Dazhuang, L. Lu, Z. Yongchuan, F. Anhua, W. Yajuan, L.J.J.C.R. Chunlei, A preparation method for mRNA-LNPs with improved properties, 364 (2023).10.1016/j.jconrel.2023.11.017 ↗
56. Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy10.1038/s41467-024-51056-8 ↗
57. Mechanisms of sepsis-induced acute lung injury and advancements of natural small molecules in its treatment10.3390/ph17040472 ↗
58. Nanotechnology approaches for inhalation treatment of lung diseases10.1016/j.jconrel.2015.07.024 ↗
59. Inhaled mRNA nanoparticles dual-targeting cancer cells and macrophages in the lung for effective transfection10.1073/pnas.2304966120 ↗
60. N. C S, K. M, N. D W, O. S, S.J.C.R.T. A F, Disulfiram is a potent inhibitor of proteases of the caspase family, 10 (1998).